Cereno Scientific nominates drug candidate CS585 in PCA Program for continued development in cardiovascular disease
Cereno Scientific (XSAT: CRNO B) today announced that drug candidate CS585 has been nominated for continued development in the preclinical Prostacyclin Analog (PCA) Program after completing initial preclinical studies. The drug candidate was nominated after demonstrating highest potential in cardiovascular disease among a set of similar molecules. CS585 will continue in its preclinical development program with the aim to provide a better treatment for patients with cardiovascular disease.
“I am pleased to see a candidate nominated in our PCA Program as it signifies progress and proven science, albeit in early stages,” said Sten R. Sörensen, CEO at Cereno. “The nomination of the drug candidate also points to a half-way milestone in the preclinical PCA Program and I look forward to its continued development. Our aim to have three clinical development programs in the portfolio within the next two years is on track.”
CS585, a small molecule, is a stable, selective, and potent IP (prostacyclin) receptor agonist. The drug candidate has demonstrated potential to significantly improve on mechanisms relevant to selected cardiovascular diseases through initial in vivo and in vitro animal models. Cereno signed an option agreement with the University of Michigan in March 2021 that gave exclusive rights to evaluate the market potential of CS585 and the possibility of in-licensing the candidate.
CS585 is currently undergoing a preclinical development program, called the PCA Program, through a research collaboration with the University of Michigan.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular disease. CS585 is a stable, selective, and potent IP (prostacyclin) receptor agonist and the CS014 program comprises HDAC inhibitors with epigenetic effects. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.